COST-EFFECTIVENESS OF ETRANACOGENE DEZAPARVOVEC FOR THE TREATMENT OF HEMOPHILIA B

被引：0
|
作者：
Sarker, J. [1 ]
Moradi, A. [2 ]
Whittington, M. [2 ]
Tice, J. A. [3 ]
Herce-Hagiwara, B. [2 ]
Fahim, S. M. [2 ]
Chu, J. [3 ]
Agboola, F. O. [2 ]
Pearson, S. [2 ]
Rind, D. M. [2 ]
Walton, S. [1 ]
机构：
[1] Univ Illinois, Chicago, IL USA
[2] Inst Clin & Econ Review, Boston, MA USA
[3] UCST Sch Med, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE555
引用
收藏
页码：S160 / S161
页数：2
相关论文
共 50 条
  • [41] 美国FDA批准Hemgenix(etranacogene dezaparvovec)用于治疗血友病B
    夏训明
    广东药科大学学报, 2023, 39 (02) : 6 - 6
  • [42] THE IMPACT OF VARYING THE TARGET POPULATION ON THE OUTCOME OF A COST-EFFECTIVENESS ANALYSIS: HEMOPHILIA B AS AN EXEMPLARY DISEASE
    Bolous, N.
    Chen, Y.
    Devidas, M.
    Reiss, U.
    Bhakta, N.
    VALUE IN HEALTH, 2023, 26 (06) : S96 - S96
  • [43] COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS
    Olasupo, O.
    Matino, D.
    Iorio, A.
    Blackhouse, G.
    Xie, F.
    Tarride, J. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S428
  • [44] EXPLORING THE POTENTIAL COST-EFFECTIVENESS OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY
    D'Angiolella, L. S.
    Cortesi, P. A.
    Ferrario, M.
    Cesana, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2018, 21 : S452 - S452
  • [45] Value contribution of Etranacogene dezaparvovec for the treatment of severe and moderately severe haemophilia B in Spain through multicriteria decision analysis (MCDA)
    Garcia Diego, Daniel-Anibal
    Jimenez-Yuste, Victor
    Nunez Vazquez, Ramiro
    Benitez Hidalgo, Olga
    Luis Poveda, Jose
    Juarez Gimenez, Juan Carlos
    Luis Trillo, Jose
    Valles, Joan-Antoni
    Perez-Santamarina, Rafael
    Badia, Xavier
    HAEMOPHILIA, 2024, 30 : 62 - 62
  • [46] Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis
    Smith, PS
    Teutsch, SM
    Shaffer, PA
    Rolka, H
    Evatt, B
    JOURNAL OF PEDIATRICS, 1996, 129 (03): : 424 - 431
  • [47] aPCC vs. rFVIIa for the Treatment of Bleeding in Patients with Acquired Hemophilia - a Cost-Effectiveness Analysis
    Kim, Chong H.
    Simmons, Sierra C.
    Bui, Chau M.
    Jiang, Ning
    Pham, Huy P.
    TRANSFUSION, 2018, 58 : 165A - 165A
  • [48] COST-EFFECTIVENESS ANALYSIS OF PROPHYLACTIC TREATMENT VERSUS A DEMAND IN YOUNG ADULTS WITH SEVERE HEMOPHILIA IN COLOMBIA
    Ordonez Molina, J. E.
    Orozco Giraldo, J. J.
    VALUE IN HEALTH, 2013, 16 (07) : A721 - A721
  • [49] COST-EFFECTIVENESS ANALYSIS OF STANDARD PROPHYLAXIS VERSUS ON-DEMAND TREATMENT IN SEVERE HEMOPHILIA A IN CHINA
    Fang, H.
    Chen, C.
    Han, L.
    Wu, J.
    VALUE IN HEALTH, 2017, 20 (05) : A219 - A220
  • [50] EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: FIRST DATA FROM THE PHASE 3 HOPE-B GENE THERAPY TRIAL
    Pipe, S. W.
    Recht, M.
    Key, N. S.
    Leebeek, F. W. G.
    Castaman, G.
    Lattimore, S. U.
    van der Valk, P.
    Peerlinck, K.
    Coppens, M.
    O'Connell, N.
    Pasi, K. J.
    Kampmann, P.
    Meijer, K.
    von Drygalski, A.
    Young, G.
    Hermans, C.
    Astermark, J.
    Klamroth, R.
    Lemons, R. S.
    Visweshwar, N.
    Crary, S.
    Kazmi, R.
    Symington, E.
    Escobar, M. A.
    Gomez, E.
    Kruse-Jarres, R.
    Kotowski, A.
    Quon, D.
    Wang, M.
    Wheeler, A. P.
    Sawyer, E. K.
    Verweij, S.
    Colletta, V.
    Bajwa, N.
    Gut, R.
    Miesbach, W.
    HAEMOPHILIA, 2021, 27 : 65 - 66
12345